Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+/HER2- advanced breast cancer - A Chinese healthcare system perspective

AIM: To evaluate the cost-effectiveness of palbociclib plus fulvestrant in the second-line treatment of women with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer based on the latest published follow-up data from the perspective of the Chinese h...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Wentao, Zheng, Miaomiao, Xia, Panpan, Hong, Wanglong, Ma, Guoqiang, Shen, Aizong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043429/
https://www.ncbi.nlm.nih.gov/pubmed/36998437
http://dx.doi.org/10.3389/fonc.2023.1068463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043429/
https://www.ncbi.nlm.nih.gov/pubmed/36998437
http://dx.doi.org/10.3389/fonc.2023.1068463

Ejemplares similares